Gland Pharma: Charting New Frontiers Of Growth
We expect revenue and PAT CAGR of 18.2% and 19.7% respectively over FY21-FY24E and recommend a HOLD with TP of Rs 4,100, implying an upside of 3%...
141 Views
Gland Pharma: Strong Product Portfolio in Injectibles
We expect Gland Pharma is well placed to grab upcoming opportunities in the injectables space in the US market, and therefore recommend HOLD with a...
118 Views
Complex products/newer markets to fortify growth pace
GLAND's 1QFY22 performance was ahead of our expectation, led by robust revenue growth across all geographies. It is progressing well on scaling up...
242 Views